Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise A. Olsen, Sean Whittaker, Eric C. Vonderheid et al.|Blood|2007Cited by 1.4k
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerElise A. Olsen, Eric C. Vonderheid, Sean Whittaker et al.|Journal of Clinical Oncology|2011Cited by 657
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaElise A. Olsen, Jean Nichols, Madeleine Duvic et al.|Journal of Clinical Oncology|2001Cited by 610
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trialH. Miles Prince, M. D’Incan, Jan Walewski et al.|The Lancet|2017Cited by 580
Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomasEric C. Vonderheid, Rein Willemze, Maria Grazia Bernengo et al.|Journal of the American Academy of Dermatology|2002Cited by 493